Summary
This International Myopia Institute Yearly Digest provides a comprehensive narrative review of myopia research published between 2019 and mid-2020. The review synthesises advances across definitions (including premyopia and pathologic myopia), genetics (identifying 336 new genetic loci), novel interventions (low-dose atropine, orthokeratology, defocus-incorporated spectacles, latanoprost), and clinical management standards. The authors highlight emerging ethical dilemmas in placebo-controlled trials, methodological considerations in reporting myopia reduction metrics, and tensions between myopia prevention and quality-of-life outcomes.
UK applicability
The clinical management recommendations and intervention evidence base reviewed here are applicable to UK optometric and ophthalmological practice, particularly regarding adoption of myopia control strategies in paediatric populations. However, the digest does not address country-specific prevalence, healthcare delivery models, or reimbursement policies relevant to the UK NHS.
Key measures
Publication volume (n=1,000 articles); number of genetic loci identified (336 new loci); categories of advancement (definitions, experimental models, genetics, interventions, clinical trials, clinical management)
Outcomes reported
A systematic review of over 1,000 peer-reviewed articles on myopia published between 2019 and mid-2020, identifying key advances in definitions, genetic loci, pharmacological and optical interventions, and clinical management strategies. The digest synthesises emerging evidence on myopia prevention and control treatments and highlights evolving ethical and methodological considerations in myopia research.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.